0001213900-16-016819.txt : 20160915
0001213900-16-016819.hdr.sgml : 20160915
20160915170709
ACCESSION NUMBER: 0001213900-16-016819
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20160915
DATE AS OF CHANGE: 20160915
EFFECTIVENESS DATE: 20160915
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: DanDrit Biotech USA, Inc.
CENTRAL INDEX KEY: 0001527728
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452259340
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-270777
FILM NUMBER: 161887730
BUSINESS ADDRESS:
STREET 1: DANDRIT BIOTECH A/S
STREET 2: FRUEBJERGVEJ 3 BOX 62
CITY: 2100 COPENHAGEN
STATE: G7
ZIP: 0
BUSINESS PHONE: 45 39179840
MAIL ADDRESS:
STREET 1: DANDRIT BIOTECH A/S
STREET 2: FRUEBJERGVEJ 3 BOX 62
CITY: 2100 COPENHAGEN
STATE: G7
ZIP: 0
FORMER COMPANY:
FORMER CONFORMED NAME: Putnam Hills Corp.
DATE OF NAME CHANGE: 20110810
D
1
primary_doc.xml
X0707
D
LIVE
0001527728
DanDrit Biotech USA, Inc.
FRUEBJERGVEJ 3 BOX 62
COPENHAGEN
G7
DENMARK
2100
(453) 917-9840
DELAWARE
None
Putnam Hills Corp.
Corporation
true
Eric
Leire
Fruebjergvej 3 Box 62
Copenhagen
G7
DENMARK
2100
Executive Officer
Director
N.
E.
Nielsen
Fruebjergvej 3 Box 62
Copenhagen
G7
DENMARK
2100
Director
Aldo
Michael Noes
Petersen
Fruebjergvej 3 Box 62
Copenhagen
G7
DENMARK
2100
Director
Biotechnology
Decline to Disclose
- 06b
false
true
false
true
true
On 4/4/16 Issuer entered into an asset purchase agreement with OncoSynergy -see 8-K filed 4/5/16. Purchase price consists of common stock outstanding prior to closing and derivative securities; acquisition subject to approval by Issuer shareholders.
10000
Livingston Securities, LLC
147364
None
None
825 THIRD AVENUE, SECOND FLOOR
NEW YORK
NY
NEW YORK
10022
All States
false
16500000
0
16500000
false
0
50000
true
0
0
false
DanDrit Biotech USA, Inc.
/s/ Dr. Eric Leire
Dr. Eric Leire
Chief Executive Officer
2016-09-15